Abstract: The invention relates to a microneedle array, in particular to an applicator system, and to the use thereof for the intradermal delivery of active ingredients in the form of salts, in particular medicinal drugs in the form of salts, wherein this microneedle array is suitable for penetrating the skin of humans or animals, and the microneedles are made of a formulation, containing at least one active ingredient in the form of a salt and at least one biodegradable polymer.

Abstract: The invention relates to a method of treating pain in a patient by applying a transdermal therapeutic system for the transdermal administration of buprenorphine for 7 days on the skin of a patient, said transdermal therapeutic system comprising a buprenorphine-containing self-adhesive layer structure comprising A) a buprenorphine-impermeable backing layer, and B) a buprenorphine-containing matrix layer on said buprenorphine-impermeable backing layer, the matrix layer comprising a) a polymer base, b) buprenorphine, and c) a carboxylic acid selected from the group consisting of oleic acid, linoleic acid, linolenic acid, levulinic acid and mixtures thereof, in an amount sufficient so that said buprenorphine is solubilized therein to form a mixture, and the carboxylic acid buprenorphine mixture forms dispersed deposits in the polymer base, and C) a skin contact layer on said buprenorphine-containing matrix layer comprising a polymer-based pressure-sensitive adhesive, and optionally wherein the buprenorphine-conta

Abstract: An adhesive mat for gluing a the onto a well includes a plate-side adhesive layer for connection with the tile by a material union and a wall-side adhesive layer for gluing onto the well. In this way, tiles can be handled in a clean and dry manner. The adhesive mat may already be connected to a tile at the manufacturer's end to thereby form a tile unit. The adhesive mat can have at least one overhang over the border of the tile, such that several such tile units can be arranged in a grid pattern with the adhesive mats overlapping.

Abstract: A transdermal therapeutic system for the transdermal administration of buprenorphine comprising a buprenorphine-containing self-adhesive layer structure having (A) a buprenorphine-impermeable backing layer, and (B) a buprenorphine-containing pressure-sensitive adhesive layer on the backing layer. The buprenorphine-containing adhesive layer comprises (a) at least one polymer-based pressure-sensitive adhesive, (b) an analgesically effective amount of buprenorphine base or a pharmaceutically acceptable salt thereof, (c) a viscosity-increasing substance in an amount of about 0.1% to about 8% of the buprenorphine-containing pressure-sensitive adhesive layer, and (d) a carboxylic acid selected from oleic acid, linoleic acid, linolenic acid, levulinic acid and mixtures thereof. The amount of the carboxylic acid is sufficient so that the analgesically effective amount of buprenorphine is solubilized in the carboxylic acid to form a mixture including the viscosity-increasing substance.

Abstract: Nicotine-containing transparent transdermal therapeutic system The invention relates to transparent therapeutic systems (TTS) which contain the active substance nicotine and which further contain at least one acid amide group as a lateral functional group. The TTS can be transparent and for discreet use. The invention also relates to methods for producing these TTS, said TTS being produced by methods using said polymers and being charged with active substance by way of a printing method.

Abstract: The invention relates to a transdermal therapeutic system (TTS), comprising a backing layer, which is permeable to the active ingredient, at least one matrix layer, comprising fentanyl or an active agent analogous to fentanyl, based on polyacrylate and a protective layer to be removed before usage, characterized in that the polyacrylate polymer is self-adhesive, free of carboxyl groups, has a saturation solubility for fentanyl of 3 to 20 wt. %, preferably of 4 to 12 and particularly of 5 to 10 wt. % and the layers contain at least 80% of the included active ingredient in a molecularly-dispersed, dissolved form.

Abstract: A system includes a vehicle, a first passive Near-Field Communication (NFC) device, and a first mobile device communicatively coupled to the vehicle and including a digital vehicle key. The first mobile device distributes the digital vehicle key to the first passive NFC device and informs the vehicle an instance in which the mobile device has distributed the digital vehicle key to the first passive NFC device.

Abstract: The invention relates to a transdermal therapeutic system (TTS), comprising a backing layer, which is permeable to the active ingredient, at least one matrix layer, comprising fentanyl or an active agent analogous to fentanyl, based on polyacrylate and a protective layer to be removed before usage, characterized in that the polyacrylate polymer is self-adhesive, free of carboxyl groups, has a saturation solubility for fentanyl of 3 to 20 wt. %, preferably of 4 to 12 and particularly of 5 to 10 wt. % and the layers contain at least 80% of the included active ingredient in a molecularly-dispersed, dissolved form.

Abstract: The invention relates to a transdermal therapeutic system (TTS), comprising a backing layer, which is permeable to the active ingredient, at least one matrix layer, comprising fentanyl or an active agent analogous to fentanyl, based on polyacrylate and a protective layer to be removed before usage, characterized in that the polyacrylate polymer is self-adhesive, free of carboxyl groups, has a saturation solubility for fentanyl of 3 to 20 wt. %, preferably of 4 to 12 and particularly of 5 to 10 wt. % and the layers contain at least 80% of the included active ingredient in a molecularly-dispersed, dissolved form.

Abstract: Method and apparatus are disclosed for end-to-end vehicle secure ECU unlock in a semi-offline environment. An example vehicle electronic control unit includes a first processor and a second processor. The first processor, when unlocked, provides diagnostic information. The second processor sends a seed value to a diagnostic tool. Additionally, the second processor, in response to receiving a second key, unlocks the first processor. The second processor, after receiving a first verifier, decrypts the first verifier to generate a new key, replaces a current key with the new key, and sends a second verifier to the diagnostic tool.

Abstract: The invention relates to a transdermal therapeutic system (TTS), comprising a backing layer, which is permeable to the active ingredient, at least one matrix layer, comprising fentanyl or an active agent analogous to fentanyl, based on polyacrylate and a protective layer to be removed before usage, characterized in that the polyacrylate polymer is self-adhesive, free of carboxyl groups, has a saturation solubility for fentanyl of 3 to 20 wt. %, preferably of 4 to 12 and particularly of 5 to 10 wt. % and the layers contain at least 80% of the included active ingredient in a molecularly-dispersed, dissolved form.

Abstract: The invention relates to a medical product for a fastening duration of at least 7 days having good skin compatibility. The medical product includes a central adhesive compartment (3) and an over-patch. The over-patch is free of active ingredients and is formed from a water-vapor-permeable back layer (1) and an adhesive polymer layer (2) that is free of active ingredients. The invention further relates to a method for the production of the foregoing medical product, and to kits of parts containing laminates of layers 1 and 2.

Abstract: The invention relates to a medical product for a fastening duration of at least 7 days having good skin compatibility. The medical product includes a central adhesive compartment (3) and an over-patch. The over-patch is free of active ingredients and is formed from a water-vapor-permeable back layer (1) and an adhesive polymer layer (2) that is free of active ingredients. The invention further relates to a method for the production of the foregoing medical product, and to kits of parts containing laminates of layers 1 and 2.

Abstract: The invention relates to a transdermal therapeutic system for administering the active substance buprenorphine. Said system comprises at least one carboxylic acid that determines the solubility of buprenorphine in the matrix layer and that can likewise be absorbed. The transdermal therapeutic system according to the invention is used in the treatment of pain and characterized by a considerably increased utilization of the active substance.

Abstract: Method and apparatus are disclosed for secure idle for a vehicle generator. An example vehicle includes an outlet external to the vehicle, a power inverter dedicated to supplying AC power to the outlet, and a powertrain control module. The powertrain control module controls the power inverter to supply first power level when a switch is in a first position and a second power level when the switch is in a second position. Additionally, the powertrain control module, after entering a secure mode, controls an engine to remain idling when an ignition switch is off.

Abstract: Method and apparatus are disclosed for status tests of wireless communication nodes of vehicles. An example vehicle includes communication nodes including a first node and a second node. The first node is to send a first of test signals to and receive a second of the test signals from the second node. The example vehicle also includes a controller to determine signal strengths of the test signals and at least partially disable passive entry passive start responsive to determining one or more of the communication nodes is impaired based upon the signal strengths.

Abstract: An access assessment tool is described for providing a technical solution for selectively controlling access to restricted information and/or implementation of restricted functionalities based on a current vehicle mode and/or validated credentials. The access assessment tool described herein controls the validation of a user or diagnostic tool requesting access to restricted information or implementation of a restricted function before allowing access to the restricted information or allowing implementation of the restricted function.

Abstract: Method and apparatus are disclosed for remote keyless entry authentication. An example remote keyless entry system includes a key fob and a vehicle. The key fob generates a secured message with a plaintext space and a ciphertext space. The vehicle (i) determines whether the key fob may be authorized based on first information in the plaintext space, (ii) decrypts an encrypted value in the ciphertext space based on a predicted full counter value, and (iii) determines whether the key fob is authorized based on second information in the encrypted value.

Abstract: Method and apparatus are disclosed for a system for keyless entry. An example vehicle includes a valet dongle, a dock configured to connect to the valet dongle; and a valet manager. The valet manager enables the valet dongle to authorize keyless entry and keyless ignition when (a) the valet dongle is removed from the dock while an ignition of the vehicle is on and (b) an authorized passcode is provided via an infotainment head unit.

Abstract: Disclosed is a method for marking film-type dosage forms, comprising at least the positioning of a film-type dosage form between two layers of a scalable packaging material, the sectional heat-scaling of the two layers of the scalable packaging material so as to obtain an edge-sealed bag containing the film-type dosage form, and the blind-embossing of the film-type dosage form contained in the edge-sealed bag through at least one of the two layers of packaging material of the edge-sealed bag.